Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Shuai Xia; Meiqin Liu; Chao Wang; Wei Xu; Qiaoshuai Lan; Siliang Feng; Feifei Qi; Linlin Bao; Lanying Du; Shuwen Liu; Chuan Qin; Fei Sun; Zheng‐Li Shi; Yun Zhu; Shibo Jiang; Lu Lu

doi:10.1038/s41422-020-0305-x

Keywords

CoronavirusVirologyLipid bilayer fusionBiologyFusion proteinCoronaviridaeViral entryVirusViral replicationCoronavirus disease 2019 (COVID-19)MedicineRecombinant DNABiochemistryGeneInfectious disease (medical specialty)Disease

Affiliated Institutions

Related Publications

Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites

Sandrine Belouzard , Victor C. Chu , Gary R. Whittaker

The coronavirus spike protein (S) plays a key role in the early steps of viral infection, with the S1 domain responsible for receptor binding and the S2 domain mediating membran...

2009 Proceedings of the National Academy o... 1160 citations

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Xiangyang Chi , Renhong Yan , Jun Zhang +21 more

Hitting SARS-CoV-2 in a new spot A key target for therapeutic antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the spike protein, a trimeric pr...

2020 Science 1543 citations

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

Xiaolong Tian , Cheng Li , Ailing Huang +8 more

The newly identified 2019 novel coronavirus (2019-nCoV) has caused more than 11,900 laboratory-confirmed human infections, including 259 deaths, posing a serious threat to human...

2020 Emerging Microbes & Infections 1257 citations

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

Kizzmekia S. Corbett , Darin K. Edwards , Sarah R. Leist +59 more

A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have ...

2020 Nature 1567 citations

Ready, Set, Fuse! The Coronavirus Spike Protein and Acquisition of Fusion Competence

Taylor Heald‐Sargent , Tom Gallagher

Coronavirus-cell entry programs involve virus-cell membrane fusions mediated by viral spike (S) proteins. Coronavirus S proteins acquire membrane fusion competence by receptor i...

2012 Viruses 349 citations

Publication Info

Year: 2020
Type: article
Volume: 30
Issue: 4
Pages: 343-355
Citations: 1402
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1402

OpenAlex

Cite This

APA Style

                            
                                
                                    Shuai Xia, 
                                
                                    Meiqin Liu, 
                                
                                    Chao Wang
                                
                                et al.
                            
                            (2020). 
                            Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. 
                            Cell Research
                            , 30
                            (4)
                            , 343-355.
                            https://doi.org/10.1038/s41422-020-0305-x
                        

Identifiers

DOI: 10.1038/s41422-020-0305-x